ECSP12011803A - Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas - Google Patents
Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicasInfo
- Publication number
- ECSP12011803A ECSP12011803A ECSP12011803A ECSP12011803A EC SP12011803 A ECSP12011803 A EC SP12011803A EC SP12011803 A ECSP12011803 A EC SP12011803A EC SP12011803 A ECSP12011803 A EC SP12011803A
- Authority
- EC
- Ecuador
- Prior art keywords
- present
- polypeptides
- relates
- cancer
- sequence
- Prior art date
Links
- 108010002350 Interleukin-2 Proteins 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 208000037581 Persistent Infection Diseases 0.000 title 1
- 239000002955 immunomodulating agent Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
- 230000002584 immunomodulator Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000000588 Interleukin-2 Human genes 0.000 abstract 2
- 210000000987 immune system Anatomy 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000055277 human IL2 Human genes 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona en general con polipéptidos cuya secuencia primaria tiene una alta homología con la secuencia de la Interleucina 2 humana (IL-2) con algunas mutaciones puntuales en la secuencia de la IL-2 nativa. Los polipéptidos de la presenten invención tienen un efecto inmunomodulador sobre el sistema inmune, que es selectivo/ preferencial sobre células T reguladoras. La presente invención también se relaciona con polipéptidos específicos cuya secuencia de aminoácidos es divulgada en la presente invención. En otro aspecto la presente invención se relaciona con las composiciones farmacéuticas que comprenden como principio activo los polipéptidos divulgados. Por último, la presente invención se relaciona con el uso terapéutico de los polipéptidos y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como cáncer y enfermedades infecciosas crónicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20090203A CU23734A1 (es) | 2009-11-27 | 2009-11-27 | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP12011803A true ECSP12011803A (es) | 2012-07-31 |
Family
ID=43646474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP12011803 ECSP12011803A (es) | 2009-11-27 | 2012-04-17 | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8759486B2 (es) |
| EP (1) | EP2505206B1 (es) |
| JP (1) | JP5680661B2 (es) |
| KR (1) | KR101484590B1 (es) |
| CN (1) | CN102665754B (es) |
| AR (1) | AR079197A1 (es) |
| AU (1) | AU2010324254B2 (es) |
| BR (1) | BR112012012025B8 (es) |
| CA (1) | CA2781173C (es) |
| CL (1) | CL2012001030A1 (es) |
| CO (1) | CO6501124A2 (es) |
| CU (1) | CU23734A1 (es) |
| EA (1) | EA021867B1 (es) |
| EC (1) | ECSP12011803A (es) |
| ES (1) | ES2643465T3 (es) |
| MX (1) | MX2012006077A (es) |
| MY (1) | MY162324A (es) |
| NZ (1) | NZ599792A (es) |
| PE (1) | PE20121636A1 (es) |
| PH (1) | PH12012500812A1 (es) |
| SG (1) | SG181089A1 (es) |
| TN (1) | TN2012000182A1 (es) |
| WO (1) | WO2011063770A2 (es) |
| ZA (1) | ZA201203762B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6093712B2 (ja) | 2010-12-22 | 2017-03-08 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン２のスーパーアゴニストおよびアンタゴニスト |
| WO2015042707A1 (en) | 2013-09-24 | 2015-04-02 | Medicenna Therapeutics Pte Ltd | Interleukin-2 fusion proteins and uses thereof |
| EP3320916B1 (en) | 2014-03-17 | 2021-09-15 | BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten | A medicament for use in a method of inducing or extending a cellular cytotoxic immune response |
| WO2015164815A1 (en) * | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| WO2017096262A1 (en) | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
| AU2017335771A1 (en) | 2016-09-28 | 2019-02-28 | Musc Foundation For Research Development | Antibodies that bind interleukin-2 and uses thereof |
| CU24483B1 (es) | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| AU2018226857B2 (en) | 2017-03-03 | 2025-01-02 | Obsidian Therapeutics, Inc. | Compositions and methods for immunotherapy |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| JP7433051B2 (ja) | 2017-06-19 | 2024-02-19 | メディシナ セラピューティクス インコーポレイテッド | Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法 |
| MA49767A (fr) | 2017-08-03 | 2021-05-26 | Synthorx Inc | Conjugués de cytokine pour le traitement de maladies auto-immunes |
| US20200299349A1 (en) | 2017-11-21 | 2020-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Partial agonists of interleukin-2 |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| BR112020018709A2 (pt) | 2018-03-28 | 2021-01-05 | Bristol-Myers Squibb Company | Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso |
| BR112020019639A2 (pt) * | 2018-03-28 | 2021-01-05 | Ascendis Pharma Oncology Division A/S | Conjugados de il-2 |
| US20210253671A1 (en) * | 2018-06-07 | 2021-08-19 | Prottech Inc. | Pharmaceutical Composition Containing Fusion Protein and Use Thereof |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CA3127689A1 (en) | 2019-02-06 | 2020-08-13 | Synthorx, Inc. | Il-2 conjugates and methods of use thereof |
| TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向ＭＡｄＣＡＭ之免疫耐受性 |
| AU2020347154A1 (en) | 2019-09-10 | 2022-03-03 | Synthorx, Inc. | IL-2 conjugates and methods of use to treat autoimmune diseases |
| MX2022007605A (es) | 2019-12-23 | 2022-07-19 | Synthorx Inc | Metodos de preparacion de n6-((2-azidoetoxi)carbonil)lisina. |
| CA3166509A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| IL298642A (en) | 2020-06-03 | 2023-01-01 | Ascendis Pharma Oncology Div A/S | il-2 sequences and uses thereof |
| EP4208474A2 (en) * | 2020-09-01 | 2023-07-12 | Takeda Pharmaceutical Company Limited | Interleukin-2 muteins and uses thereof |
| PE20240123A1 (es) | 2020-09-04 | 2024-01-22 | Shandong Simcere Biopharmaceutical Co Ltd | Mutante de il-2 y aplicacion de este |
| EP4232071A4 (en) | 2020-10-23 | 2024-08-28 | Asher Biotherapeutics, Inc. | FUSIONS WITH CD8 ANTIGEN-BINDING MOLECULES TO MODULATE IMMUNE CELL FUNCTION |
| IL302114A (en) | 2020-10-29 | 2023-06-01 | Bristol Myers Squibb Co | Fusion proteins for the treatment of disease |
| CN117321189A (zh) | 2021-04-30 | 2023-12-29 | 泰根制药有限公司 | 淋巴细胞的单血管扩增 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| JP2025541604A (ja) | 2022-11-02 | 2025-12-22 | ティゲン・ファーマ・ソシエテ・アノニム | リンパ球の拡大 |
| WO2024261339A1 (en) | 2023-06-23 | 2024-12-26 | Tigen Pharma Sa | Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| JP3024311B2 (ja) | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Ｉｌ−２受容体重鎖に結合するポリペプチド |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| US6906170B1 (en) | 1998-08-21 | 2005-06-14 | Yeda Research And Development Co. Ltd. | Anti-inflammatory peptides derived from IL-2 and analogues thereof |
| BR0214650A (pt) | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| CA2656700A1 (en) * | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| WO2009061853A2 (en) | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| DE102008023820A1 (de) * | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
-
2009
- 2009-11-27 CU CU20090203A patent/CU23734A1/es active IP Right Grant
-
2010
- 2010-11-25 AR ARP100104366A patent/AR079197A1/es active IP Right Grant
- 2010-11-26 PH PH1/2012/500812A patent/PH12012500812A1/en unknown
- 2010-11-26 JP JP2012540281A patent/JP5680661B2/ja not_active Expired - Fee Related
- 2010-11-26 MY MYPI2012002130A patent/MY162324A/en unknown
- 2010-11-26 WO PCT/CU2010/000005 patent/WO2011063770A2/es not_active Ceased
- 2010-11-26 EA EA201290395A patent/EA021867B1/ru not_active IP Right Cessation
- 2010-11-26 ES ES10803437.2T patent/ES2643465T3/es active Active
- 2010-11-26 BR BR112012012025A patent/BR112012012025B8/pt not_active IP Right Cessation
- 2010-11-26 AU AU2010324254A patent/AU2010324254B2/en not_active Ceased
- 2010-11-26 US US13/512,429 patent/US8759486B2/en active Active
- 2010-11-26 CA CA2781173A patent/CA2781173C/en active Active
- 2010-11-26 MX MX2012006077A patent/MX2012006077A/es active IP Right Grant
- 2010-11-26 NZ NZ599792A patent/NZ599792A/en not_active IP Right Cessation
- 2010-11-26 KR KR1020127010828A patent/KR101484590B1/ko not_active Expired - Fee Related
- 2010-11-26 PE PE2012000720A patent/PE20121636A1/es not_active Application Discontinuation
- 2010-11-26 CN CN201080053369.9A patent/CN102665754B/zh not_active Expired - Fee Related
- 2010-11-26 SG SG2012039053A patent/SG181089A1/en unknown
- 2010-11-26 EP EP10803437.2A patent/EP2505206B1/en active Active
-
2012
- 2012-04-17 EC ECSP12011803 patent/ECSP12011803A/es unknown
- 2012-04-20 TN TNP2012000182A patent/TN2012000182A1/en unknown
- 2012-04-23 CL CL2012001030A patent/CL2012001030A1/es unknown
- 2012-05-23 ZA ZA2012/03762A patent/ZA201203762B/en unknown
- 2012-06-06 CO CO12095471A patent/CO6501124A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
| CU23923B1 (es) | Polipéptidos derivados de la il-2 con actividad agonista | |
| BR112017025108A2 (pt) | compostos seletivos de pyy e usos dos mesmos | |
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| BR112012020839A2 (pt) | vacinas para uso na profilaxe e tratamento de doença de vírus da influenza | |
| MX2021005358A (es) | Metodos y composiciones que comprenden polipeptidos recombinantes purificados. | |
| CR20160117A (es) | Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos | |
| MX386142B (es) | COMPOSICIONES INMUNOGÉNICAS PARA EL CORONAVIRUS DEL SÍNDROME RESPIRATORIO DE ORIENTE MEDIO (MERS-CoV) Y SUS USOS. | |
| JOP20200039A1 (ar) | مُستحضر صيدلي يشتمل على hcg مأشوب | |
| EA201590343A1 (ru) | Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| CO7010783A2 (es) | Proteína naglu humana recombinante y usos de la misma | |
| EA201490610A1 (ru) | Соединения и способы усиления врожденных иммунных ответов | |
| EA201590667A1 (ru) | Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний | |
| BR112015022758A2 (pt) | derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia | |
| CR20140475A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| BR112015013125A2 (pt) | tratamento de lesões orais usando composições de matrix placentário extracelular | |
| BR112014026407A2 (pt) | formulação de vacina líquida | |
| BR112015015250A2 (pt) | derivados de pirrolidina, composições farmacêuticas e usos dos mesmos | |
| MX392532B (es) | Glicoproteinas recombinantes y sus usos. | |
| CO7400865A2 (es) | Polipeptidos derivados del tgfbeta y sus usos | |
| PY1939780A (es) | Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida | |
| BR112018016715A2 (pt) | ?formulações de oritavancina? | |
| RU2013141485A (ru) | Биологически активные пептиды | |
| EA201992746A3 (ru) | Рекомбинантные гликопротеиды и их применения | |
| AR098154A1 (es) | Glicoproteínas recombinantes y sus usos |